Persistent Cytomegalovirus Retinitis following Hematopoietic Stem Cell
Transplantation Treated with Viral-Specific T Cells
Abstract
Cytomegalovirus retinitis (CMVR) following hematopoietic stem cell
transplantation (HCT) for a primary immunodeficiency is a rare but
highly morbid condition with potential irreversible consequences despite
optimal antiviral pharmacotherapy. Viral-specific T cells (VSTs) pose a
promising and safe approach eradicating intractable viral disease. We
describe the case of a 21-month-old male with Wiskott-Aldrich syndrome
(WAS) and CMVR post-HCT with sustained long-term virologic and clinical
response after CMV-specific T cell therapy. This case highlights the
need to consider VSTs as an adjunct upfront strategy in refractory CMVR
and for routine ophthalmologic screening and surveillance in high-risk
patients post-HCT.